HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

AcPhe(ornithine- Pro- cyclohexylamine- Trp- Arg)

Also Known As:

AcF-(OP(D-Cha)WR); AcF-(OPdChaWR); PMX 53; PMX-53; PMX53 cpd

Networked: 12 relevant articles (3 outcomes, 1 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Polycyclic Compounds: 6
- Macrocyclic Compounds: 15
  - Cyclic Peptides: 530
    - AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg): 12
Amino Acids, Peptides, and Proteins: 1
- Peptides: 82426
  - Cyclic Peptides: 530
    - AcPhe(ornithine-Pro-cyclohexylamine-Trp-Arg): 12

Experts

1.	Taylor, Stephen M: 6 articles (01/2006 - 04/2002)
2.	Shiels, Ian A: 5 articles (01/2006 - 04/2002)
3.	Woodruff, Trent M: 5 articles (01/2006 - 04/2002)
4.	Fairlie, David P: 3 articles (01/2004 - 04/2002)
5.	Reid, Robert C: 3 articles (01/2004 - 04/2002)
6.	Proctor, Lavinia M: 2 articles (01/2006 - 08/2005)
7.	Taylor, S M: 2 articles (12/2004 - 12/2001)
8.	Arumugam, Thiruma V: 2 articles (01/2004 - 04/2002)
9.	Cotechini, Tiziana: 1 article (10/2018)
10.	Coussens, Lisa M: 1 article (10/2018)

Related Diseases

1.	Colitis 08/01/2005 - "These studies suggest that resistance to intestinal metabolism by HC-[OP(d-Cha)WR] may result in increased local concentrations of the drug in the colon, thus affording efficacy with markedly lower oral doses than AcF-[OP(d-Cha)WR] against TNBS-colitis. " 08/01/2005 - "One metabolically stable analog, HC-[OP(d-Cha)WR], was then evaluated pharmacokinetically and investigated at a range of doses (0.03-10 mg/kg/day p.o.) in the 8-day rat TNBS-colitis model, against the comparator drug AcF-[OP(d-Cha)WR]. " 08/01/2005 - "However, in the rat TNBS-colitis model, HC-[OP(d-Cha)WR] was effective at reducing mortality, colon edema, colon macroscopic scores, and increasing food consumption and body weights, at 10- to 30-fold lower oral doses than AcF-[OP(d-Cha)WR]. " 08/01/2005 - "We have previously shown that complement factor 5a (C5a) plays a role in the pathogenesis of 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in rats by using the selective, orally active C5a antagonist AcF-[OP(d-Cha)WR]. "
2.	Carcinoma (Carcinomatosis) 10/08/2018 - "Therapeutic inhibition of C5aR1 via the peptide antagonist PMX-53 improved efficacy of paclitaxel chemotherapy associated with increased presence and cytotoxic properties of CXCR3+ effector memory CD8+ T cells in carcinomas, dependent on both macrophage transcriptional programming and IFNγ. "
3.	Arthritis (Polyarthritis) 09/01/2002 - "To determine if the new, orally active C5a receptor antagonist, the cyclic peptide AcF-[OPdChaWR], reduces the severity of pathology in a rat model of immune-mediated monarticular arthritis. "
4.	Edema (Dropsy) 06/01/2006 - "The once-daily injection of the C5a receptor antagonist AcF-[OPdChaWR] reduced mechanical allodynia and edema in the incised hind paw. " 08/01/2005 - "However, in the rat TNBS-colitis model, HC-[OP(d-Cha)WR] was effective at reducing mortality, colon edema, colon macroscopic scores, and increasing food consumption and body weights, at 10- to 30-fold lower oral doses than AcF-[OP(d-Cha)WR]. " 04/01/2002 - "Pretreatment with either a single intravenous dose (1 mg/kg), or a single oral dose (10 mg/kg) of AcF-(OPdChaWR) significantly inhibited I/R induced neutropenia, the elevated serum levels of tumor necrosis factor-alpha, haptoglobin, and plasma aspartate aminotransferase, as well as intestinal edema. "
5.	Wounds and Injuries (Trauma) 04/01/2002 - "We have studied the action of an orally active complement factor 5a (C5a) receptor antagonist, the cyclic peptide AcF-(OPdChaWR) [Ac-Phe(Orn-Pro-d-cyclohexylalanine-Trp-Arg)] against local and remote intestinal I/R injuries in rats. "

Related Drugs and Biologics

1.	hydrocinnamate- cyclo(ornithyl- prolyl- cyclohexylalanyl- tryptophyl- arginyl)
2.	Anaphylatoxin C5a Receptor
3.	Cyclic Peptides
4.	Paclitaxel (Taxol)
5.	Peptides (Polypeptides)
6.	Factor Va
7.	Complement System Proteins (Complement)
8.	Complement C5a (Complement 5a)
9.	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)
10.	Sulfonic Acids

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Oral Administration